Oncology therapeutics company Mosaic Therapeutics has appointed Thomas Fuchs as its CEO. 

Fuchs has over 25 years of experience in leadership positions across early drug development, commercialisation and life cycle management, serving in senior oncology biopharma leadership roles in both oncology-focused biotech and big pharma. He was most recently CEO at Cimeio Therapeutics, where he led the early company build backed by a $50 million Series A financing raise and secured a significant strategic collaboration agreement with Kyowa Kirin. 

He previously spent 15 years at Roche-Genentech, serving in senior leadership roles across the Global Haematology franchise.  

Fuchs will now lead Mosaic Therapeutics to advance its pipeline of proprietary drug combination programmes into the clinic, and through a planned Series B financing round. 

“Mosaic has built a uniquely differentiated pipeline of drug combination programmes with huge potential to bring significant therapeutic benefit to cancer patients,” said Fuchs. “I am excited to be joining at this critical juncture. I look forward to working with the leadership team to drive the ongoing fundraising and advance the development of Mosaic’s pipeline into the clinic.” 

Mosaic is currently applying its advanced experimental and computational platform to identify oncology combinations that have synergistic activity in biomarker-defined patient populations. The company’s pipeline of combination programmes is anchored by ASTX029, an ERK1/2 inhibitor, and ASTX295, an MDM2 antagonist, both in-licensed from Astex Pharmaceuticals in April 2025.  

Bruno Quinney, Content Team, DDW